Author Interviews, Menopause, NEJM, Osteoporosis / 04.01.2014
Osteoporosis: Improving Bone Mineral Density Postmenopause with Monoclonal Antibody Romosozumab
MedicalResearch.com Interview with
Michael McClung, MD
Founding Director, Oregon Osteoporosis Center
5050 NE Hoyt Street, Suite 626
Portland, OR 97213
MedicalResearch.com: What are the main findings of the study?
Dr. McClung: In this Phase 2 trial, each of five romosozumab dose regimens significantly increased BMD compared with pooled placebo groups at the lumbar spine, total hip and femoral neck regions (all p<0.001). The largest increases were observed with the romosozumab 210 mg once-monthly dose, with mean increases, compared with baseline, of 11.3 percent at the lumbar spine, 4.1 percent at the total hip and 3.7 percent at the femoral neck.
(more…)